Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE)

Trial Details

  • 100 patients will be taking part in this study
  • Condition: Crohn's Disease
  • Intervention: Drug: Vedolizumab Drug: Placebo
  • Clinic: GI Research Institute Suite 770-1190 Hornby Street, Vancouver, British Columbia, Canada

Summary

The purpose of this study is to evaluate perianal fistula healing at Week 30 in 2 different dose regimens of vedolizumab intravenous (IV) 300 milligram (mg) in participants with fistulizing Crohn's disease (CD).

Researchers

Brian bressler headshot for dt trial listings
Gastroenterologist

Full Trial Details